Elucida Oncology, Inc., is a privately-held biotechnology company focused on the development of life-changing therapeutics based on C’Dots, our novel, ultra-small cancer drug delivery platform. C’Dot-Drug-Conjugates, or CDCs, are novel therapeutics that can substantially increase the concentration of highly potent cytotoxic drugs inside difficult to treat tumors with reduced systemic exposure due to their unique Target or Clear properties.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Folate Receptor Alpha-targeted C’Dot Drug Conjugate (CDC)
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
